Abeona Therapeutics appoints Vasanthavada as CCO, Head of BD

Abeona Therapeutics announced the appointment of Madhav Vasanthavada, Ph.D., M.B.A. to the role of Chief Commercial Officer, CCO, and Head of Business Development, BD, effective immediately. In this capacity, in addition to his current BD responsibilities, Dr. Vasanthavada will oversee all aspects of commercial strategy, planning and operations as Abeona prepares for a potential launch of EB-101, its investigational, genetically engineered autologous cell therapy for recessive dystrophic epidermolysis bullosa. Over the past year, as Abeona’s Head of BD, Dr. Vasanthavada’s efforts to assess EB-101’s commercial opportunity informed the Company’s strategy to prepare for a U.S. commercial launch without depending on a partner.